TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37935133

Group type: EXPERIMENTAL
Intervention: Short-term MBT (5 months)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Long-term MBT (14 months)
Number of subjects: 166
Study: 37935200

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Water fasting (WF)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 37935304

Group type: EXPERIMENTAL
Intervention: Gain-framed $100 incentive
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Gain-framed $200 incentive
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Loss-framed $100 incentive
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Loss-framed $200 incentive
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: All incentive groups
Number of subjects: 330
Study: 37935416

Group type: EXPERIMENTAL
Intervention: Cognitively stimulating semistructured conversations via internet/webcam 4 times per week for 6 months, then twice per week for an additional 6 months; plus weekly 10 minutes telephone check-ins
Number of subjects: 186

Group type: COMPARATOR
Intervention: Weekly 10 minutes telephone check-ins
Number of subjects: 186
Study: 37935475

Group type: EXPERIMENTAL
Intervention: Theory of Mind (ToM) psychotherapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Health education (active control)
Number of subjects: 28
Study: 37935477

Group type: EXPERIMENTAL
Intervention: Paroxetine treatment for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 37935524

Group type: EXPERIMENTAL
Intervention: Niraparib alone after carboplatin/paclitaxel
Number of subjects: 970

Group type: COMPARATOR
Intervention: Niraparib in combination with bevacizumab after carboplatin/paclitaxel
Number of subjects: 970
Study: 37935531

Group type: COMPARATOR
Intervention: MFG (family-strengthening intervention)
Number of subjects: 89

Group type: COMPARATOR
Intervention: G-CBT (group-cognitive behavioral therapy)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 89
Study: 37935564

Group type: EXPERIMENTAL
Intervention: Immune-enriched TME subtype
Number of subjects: 271
Study: 37935631

Group type: EXPERIMENTAL
Intervention: Abemaciclib in combination with fulvestrant
Number of subjects: 2436

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2436
Study: 37935652

Group type: EXPERIMENTAL
Intervention: Successful reperfusion after 1-3 recanalization attempts
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Successful reperfusion after 4 or more recanalization attempts
Number of subjects: 1078

Group type: COMPARATOR
Intervention: Comparison with large vessel occlusions (LVO)
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Symptomatic intracranial hemorrhage
Number of subjects: 1078
Study: 37935839

Group type: EXPERIMENTAL
Intervention: Children born to mothers with PCOS
Number of subjects: 556

Group type: COMPARATOR
Intervention: Children born to mothers without PCOS
Number of subjects: 556
Study: 37935913

Group type: EXPERIMENTAL
Intervention: Serum kisspeptin on day 21 after FET
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Serum kisspeptin on day 28 after FET
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Serum kisspeptin on day 14 after FET
Number of subjects: 178

Group type: COMPARATOR
Intervention: Serum HCG on days 21 and 28
Number of subjects: 178
Study: 37935977

Group type: EXPERIMENTAL
Intervention: Daunorubicin and cytarabine (DA)
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Idarubicin with higher dose cytarabine (IA)
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Idarubicin with higher dose cytarabine and vorinostat (IA+V)
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Favorable cytogenetics subset with DA
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Higher dose cytarabine (with or without vorinostat)
Number of subjects: 738
Study: 37935997

Group type: EXPERIMENTAL
Intervention: RPF group (n=95)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: RVF group (n=38)
Number of subjects: 159

Group type: COMPARATOR
Intervention: RPF group
Number of subjects: 159

Group type: COMPARATOR
Intervention: RVF group
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Male RPF group
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Female RPF group
Number of subjects: 159
Study: 37936126

Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment (palliative intent)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment (curative intent)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Routine laboratory parameters (CA 19-9, CA-125, CRP, CEA, albumin)
Number of subjects: 75
Study: 37936136

Group type: EXPERIMENTAL
Intervention: Sensorimotor capabilities (specifically stereognosis and barognosis)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: MTT measure of stereognosis
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: ESRS and MTT measure of barognosis
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Side effects of drugs and duration of illness
Number of subjects: 27
Study: 37936166

Group type: EXPERIMENTAL
Intervention: Anlotinib 12 mg once daily on days 1-14 every 3 weeks until disease progression or intolerable toxicities
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 39
Study: 37936218

Group type: EXPERIMENTAL
Intervention: Specialized telephone counseling
Number of subjects: 577

Group type: COMPARATOR
Intervention: State Quitline referral
Number of subjects: 577
Study: 37936331

Group type: EXPERIMENTAL
Intervention: Antibacterial therapeutic clothing (chitosan) + standard topical treatment
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Antibacterial therapeutic clothing (silver) + standard topical treatment
Number of subjects: 159

Group type: COMPARATOR
Intervention: Standard therapeutic clothing + standard topical treatment
Number of subjects: 159
Study: 37936408

Group type: EXPERIMENTAL
Intervention: Long-acting muscarinic antagonist therapy
Number of subjects: 1043

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (ICS) therapy
Number of subjects: 1043

Group type: EXPERIMENTAL
Intervention: Active smoking
Number of subjects: 1043

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 1043

Group type: EXPERIMENTAL
Intervention: Hill and stair climbing (from the COPD Assessment Test)
Number of subjects: 1043
Study: 37936551

Group type: EXPERIMENTAL
Intervention: Adherence support strategies including monthly counselling sessions with drug-level feedback (DLF), optional daily SMS reminders, weekly phone or SMS check-ins, peer support clubs, and additional counselling.
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Counselling sessions with DLF provided at 54.3% of sessions.
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: In-person clubs and weekly calls as support strategies.
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Qualitative adherence support strategies.
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Implementation programmes offering a menu of support options.
Number of subjects: 247
Study: 37936652

Group type: EXPERIMENTAL
Intervention: Monovalent SARS-CoV-2 recombinant protein vaccine with AS03-adjuvant (10 μg of the spike protein from the ancestral D614 strain)
Number of subjects: 10114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10114

Group type: EXPERIMENTAL
Intervention: Monovalent SARS-CoV-2 recombinant protein vaccine with AS03-adjuvant
Number of subjects: 10114
Study: 37936658

Group type: EXPERIMENTAL
Intervention: Floatation-REST
Number of subjects: 68

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 68
Study: 37936687

Group type: EXPERIMENTAL
Intervention: QL1604 at 3 mg/kg Q2W
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: QL1604
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: QL1604 at 3 mg/kg (Q2W and Q3W) and 200 mg (Q3W)
Number of subjects: 35
Study: 37936699

Group type: EXPERIMENTAL
Intervention: T-cell data
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pre-RSV season T-cell phenotypes
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Immunological parameters evaluation
Number of subjects: 51
Study: 37936786

Group type: EXPERIMENTAL
Intervention: Anplag® 90mg (Ticagrelor) tablet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brilinta® 90 mg (Ticagrelor) tablet
Number of subjects: 0
Study: 37937287

Group type: EXPERIMENTAL
Intervention: Direct wire pacing (DWP) during FFR measurement
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard method (without DWP)
Number of subjects: 94
Study: 37937305

Group type: EXPERIMENTAL
Intervention: Greater depressive symptoms
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Movement evoked pain (MEP)
Number of subjects: 33
Study: 37937322

Group type: EXPERIMENTAL
Intervention: Fatigue and Activity Management Education for Work (FAME-W) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37937397

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nivolumab or pembrolizumab alone
Number of subjects: 0
Study: 37937444

Group type: EXPERIMENTAL
Intervention: Immunochemotherapy with low-dose radiotherapy (LDRT) and conventionally fractionated radiotherapy (CFRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immunochemotherapy without radiotherapy (control group)
Number of subjects: 0
Study: 37937645

Group type: EXPERIMENTAL
Intervention: Sirolimus for 12 or more months
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Sirolimus for 2 years
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Sirolimus in PIK3CA-mutated patients
Number of subjects: 132
Study: 37937763

Group type: EXPERIMENTAL
Intervention: Osimertinib-chemotherapy
Number of subjects: 557

Group type: COMPARATOR
Intervention: Osimertinib
Number of subjects: 557
Study: 37937777

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 37937851

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPI Withdrawal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPI Initiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Non-PPI Users)
Number of subjects: 0
Study: 37938055

Group type: EXPERIMENTAL
Intervention: Blood lead (BL) concentration measured by inductively coupled plasma mass spectrometry, baseline concentration 4.35 μg/dL, increased 3.17-fold over follow-up (median: 2.03 years; range: 0.92-6.45 years).
Number of subjects: 234
Study: 37938095

Group type: EXPERIMENTAL
Intervention: ACLR (anterior cruciate ligament reconstruction)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (age, sex, and activity matched)
Number of subjects: 20
Study: 37938137

Group type: EXPERIMENTAL
Intervention: Total femur replacement after tumor resection
Number of subjects: 0
Study: 37938431

Group type: EXPERIMENTAL
Intervention: Survivors of childhood ALL and NHL
Number of subjects: 6511
Study: 37938475

Group type: EXPERIMENTAL
Intervention: COVID-19 infection
Number of subjects: 2261

Group type: EXPERIMENTAL
Intervention: COVID-19 hospitalization
Number of subjects: 2261

Group type: COMPARATOR
Intervention: COVID-19 infection rate ratio during wave 1
Number of subjects: 2261

Group type: COMPARATOR
Intervention: COVID-19 hospitalization rate ratio during wave 1
Number of subjects: 2261

Group type: COMPARATOR
Intervention: COVID-19 infection rate ratio during wave 2
Number of subjects: 2261

Group type: COMPARATOR
Intervention: COVID-19 hospitalization rate ratio during wave 2
Number of subjects: 2261
Study: 37938495

Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESA)
Number of subjects: 8381

Group type: COMPARATOR
Intervention: No ESA
Number of subjects: 8381
Study: 37938560

Group type: EXPERIMENTAL
Intervention: Intravenous methylphenidate (fast delivery)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral methylphenidate (slow delivery)
Number of subjects: 20
Study: 37938561

Group type: EXPERIMENTAL
Intervention: Dendritic Cell (DC) vaccines
Number of subjects: 35
Study: 37938599

Group type: EXPERIMENTAL
Intervention: Vaccination status (worst vaccination status)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age, fatigue, and current anxiety
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Severity of disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comorbidities and recent headaches
Number of subjects: 0
Study: 37938844

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 3731

Group type: EXPERIMENTAL
Intervention: Self-reported functional capacity measures (METs, ability to climb 1 floor, level of regular physical activity)
Number of subjects: 3731

Group type: COMPARATOR
Intervention: Clinical scores (RCRI, age)
Number of subjects: 3731
Study: 37938854

Group type: EXPERIMENTAL
Intervention: Laser epilation (LE)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 302
Study: 37938871

Group type: EXPERIMENTAL
Intervention: Group-based acceptance and commitment therapy (ACT), 7 sessions of 45-60 min over 4 weeks
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 140
Study: 37938875

Group type: EXPERIMENTAL
Intervention: In-clinic monitoring every 3 months
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: In-clinic monitoring every 6 months
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Online monitoring every 3 months
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Online monitoring every 6 months
Number of subjects: 442
Study: 37938917

Group type: EXPERIMENTAL
Intervention: Loop Gain measurement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37939111

Group type: EXPERIMENTAL
Intervention: Inoserp PAN-AFRICA antivenom (IPA), administered 2 to 4 vials based on symptoms, renewed every 2 hours if needed.
Number of subjects: 447
Study: 37939122

Group type: EXPERIMENTAL
Intervention: 131I-anti-CD45 radioimmunotherapy
Number of subjects: 25
Study: 37939124

Group type: EXPERIMENTAL
Intervention: Olaparib plus Durvalumab
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Olaparib plus Durvalumab with Bevacizumab
Number of subjects: 114
Study: 37939133

Group type: EXPERIMENTAL
Intervention: Intravenous nivolumab followed by maximal safe resection and an intracerebral injection of ipilimumab alone or combined with nivolumab, biweekly adjuvant nivolumab up to five times.
Number of subjects: 24
Study: 37939141

Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF; 50/200/25 mg)
Number of subjects: 33
Study: 37939147

Group type: EXPERIMENTAL
Intervention: ICG
Number of subjects: 258

Group type: COMPARATOR
Intervention: non-ICG
Number of subjects: 258
Study: 37939259

Group type: EXPERIMENTAL
Intervention: Intratumoral toll-like receptor 9 (TLR9) agonist with local low-dose radiation and ibrutinib
Number of subjects: 0
Study: 37939264

Group type: EXPERIMENTAL
Intervention: Combined hormonal contraceptives (CHCs) cessation
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (women without CHC)
Number of subjects: 66
Study: 37939262

Group type: EXPERIMENTAL
Intervention: 5F11-Ts (anti-CD30 CAR T cells)
Number of subjects: 21
Study: 37939328

Group type: EXPERIMENTAL
Intervention: Cluster-randomized workplace intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 37939397

Group type: EXPERIMENTAL
Intervention: Exhaled breath condensate (EBC) from patients with confirmed PE
Number of subjects: 77

Group type: COMPARATOR
Intervention: Exhaled breath condensate (EBC) from controls
Number of subjects: 77
Study: 37939520

Group type: EXPERIMENTAL
Intervention: Infant massage training
Number of subjects: 60
Study: 37939628

Group type: EXPERIMENTAL
Intervention: CGA-guided interventions in addition to oncological standard care
Number of subjects: 181

Group type: COMPARATOR
Intervention: Oncological care alone
Number of subjects: 181
Study: 37940142

Group type: EXPERIMENTAL
Intervention: Live zoster vaccine
Number of subjects: 1505647
Study: 37940151

Group type: EXPERIMENTAL
Intervention: uCaP microRNA biomarker model (miR-222-3p, miR-24-3p, miR-30c-5p)
Number of subjects: 0
Study: 37940161

Group type: EXPERIMENTAL
Intervention: PREPARED strategy
Number of subjects: 840

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 840
Study: 37940323

Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of iodine-124 labeled amyloid-reactive peptide p5+14
Number of subjects: 0
Study: 37940349

Group type: EXPERIMENTAL
Intervention: Assessment of the excursion of the ZOA using a linear probe
Number of subjects: 75

Group type: COMPARATOR
Intervention: Assessment of the excursion of the DOD using a curvilinear probe
Number of subjects: 75

Group type: COMPARATOR
Intervention: Assessment of the thickening fraction of the ZOA
Number of subjects: 75
Study: 37940357

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment (7-day course)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 50
Study: 37940377

Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation (PPV)
Number of subjects: 4876

Group type: COMPARATOR
Intervention: No PPV
Number of subjects: 4876

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 4876
Study: 37940383

Group type: EXPERIMENTAL
Intervention: Pegunigalsidase alfa
Number of subjects: 77

Group type: COMPARATOR
Intervention: Agalsidase beta
Number of subjects: 77
Study: 37940387

Group type: EXPERIMENTAL
Intervention: Neuroform Atlas Stent System (used for treatment of proximal ICA aneurysms)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Neuroform Atlas Stent System (used for treatment of distal anterior circulation aneurysms)
Number of subjects: 182
Study: 37940433

Group type: EXPERIMENTAL
Intervention: Extended antibiotic therapy (10 days of broad-spectrum antibiotics: piperacillin/tazobactam converted to amoxicillin/clavulanic acid at discharge)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Extended antibiotic therapy
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard perioperative antibiotics (single dose before incision)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard perioperative antibiotics
Number of subjects: 87
Study: 37940446

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks plus enzalutamide 160 mg orally once daily
Number of subjects: 102
Study: 37940671

Group type: EXPERIMENTAL
Intervention: 50% RNAi-based amylose-only barley flour (AmOn) and 50% wheat flour
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 50% hulless barley and 50% wheat flour
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 75% hulless barley and 25% wheat flour
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 50% RNAi-based amylose-only barley flour (AmOn)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All barley breads
Number of subjects: 20
Study: 37940915

Group type: EXPERIMENTAL
Intervention: Attendance in Recovery Colleges (RCs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-creation with RC students
Number of subjects: 0
Study: 37940936

Group type: EXPERIMENTAL
Intervention: Treviamet® & Treviamet XR® (Sitagliptin with Metformin)
Number of subjects: 188
Study: 37941012

Group type: EXPERIMENTAL
Intervention: Stereotactic arrhythmia radioablation (STAR) with dose escalation from 27.0 Gy to a maximum of 35.1 Gy while keeping the planning target volume (PTV) dose constant at 25 Gy.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Stereotactic arrhythmia radioablation (STAR) with dose escalation.
Number of subjects: 15
Study: 37941050

Group type: EXPERIMENTAL
Intervention: H-GAP
Number of subjects: 20

Group type: COMPARATOR
Intervention: H-Health
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Implants
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Microbiome
Number of subjects: 20
Study: 37941073

Group type: EXPERIMENTAL
Intervention: Liberal fluid management (high volume)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Restricted fluid management (low volume)
Number of subjects: 50
Study: 37941087

Group type: EXPERIMENTAL
Intervention: Health-social partnership programme (4 Zoom sessions and 4 telephone calls)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Monthly social telephone call from a trained research assistant
Number of subjects: 100
Study: 37941113

Group type: EXPERIMENTAL
Intervention: Clazakizumab (humanized monoclonal antibody that neutralizes interleukin-6)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 37941409

Group type: EXPERIMENTAL
Intervention: alloTSCT
Number of subjects: 217

Group type: COMPARATOR
Intervention: autoTSCT
Number of subjects: 217
Study: 37941470

Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI) 80 u twice weekly for 6 months
Number of subjects: 19
Study: 37941561

Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic therapy (NAST)
Number of subjects: 163
Study: 37941759

Group type: EXPERIMENTAL
Intervention: Hula intervention, 6 months, twice per week, 60 minutes each session, plus 60 minutes of home practice per week.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group, no immediate intervention.
Number of subjects: 0
Study: 37941823

Group type: EXPERIMENTAL
Intervention: 14 avocados/family/week
Number of subjects: 72

Group type: COMPARATOR
Intervention: 3 avocados/family/week
Number of subjects: 72
Study: 37941845

Group type: EXPERIMENTAL
Intervention: Paclitaxel-drug-coated balloon (DCB) after bare-metal stent (BMS) implantation
Number of subjects: 223

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS) only
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: DCB-combined strategy
Number of subjects: 223

Group type: COMPARATOR
Intervention: BMS
Number of subjects: 223
Study: 37941848

Group type: EXPERIMENTAL
Intervention: Garmin Vivosmart 4 watch
Number of subjects: 18

Group type: COMPARATOR
Intervention: Garmin HRM-DUAL™ chest-worn HR monitors
Number of subjects: 18
Study: 37941888

Group type: EXPERIMENTAL
Intervention: Early Functional Mobilization (EFM) group - loading allowed immediately after surgery
Number of subjects: 86

Group type: COMPARATOR
Intervention: Comparison group - loading allowed at 2 weeks postoperatively
Number of subjects: 86